NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia. The company is also developing NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a clinical stage indoleamine-2, 3-dioxygenase pathway inhibitor. In addition, it is developing tergenpumatucel-L and dorgenmeltucel-L that are in Phase II clinical trials for treating patients with advanced lung cancer and melanoma; and CRLX101 and CRLX301, which are in early clinical development to treat patients with advanced solid malignancies. The company has strategic collaboration agreement with AstraZeneca to evaluate the combination of indoximod and durvalumab, an anti-PD-L1 monoclonal antibody for treating patients with metastatic pancreatic cancer; Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe and Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorMedical
Phone515-296-5555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.47 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions
What is NewLink Genetics' stock symbol?
NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."
How were NewLink Genetics' earnings last quarter?
NewLink Genetics Corp (NASDAQ:NLNK) announced its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.22. The biotechnology company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $2.10 million. NewLink Genetics had a negative return on equity of 42.86% and a negative net margin of 429.65%. View NewLink Genetics' Earnings History.
When is NewLink Genetics' next earnings date?
What price target have analysts set for NLNK?
6 Wall Street analysts have issued 12 month price objectives for NewLink Genetics' shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate NewLink Genetics' share price to reach $5.00 in the next year. This suggests a possible upside of 163.2% from the stock's current price. View Analyst Price Targets for NewLink Genetics.
What is the consensus analysts' recommendation for NewLink Genetics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.
What are Wall Street analysts saying about NewLink Genetics stock?
Here are some recent quotes from research analysts about NewLink Genetics stock:
- 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (3/6/2019)
- 2. Cantor Fitzgerald analysts commented, "Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point." (4/16/2018)
Has NewLink Genetics been receiving favorable news coverage?
News stories about NLNK stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NewLink Genetics earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of NewLink Genetics' key competitors?
Some companies that are related to NewLink Genetics include Clover (CLV), AC Immune (ACIU), Syros Pharmaceuticals (SYRS), Cellular Biomedicine Group (CBMG), Merus (MRUS), Akumin (AKU), Karyopharm Therapeutics (KPTI), Harpoon Therapeutics (HARP), Medical Developments (MVP), Benchmark (BMK), Evelo Biosciences (EVLO), Kala Pharmaceuticals (KALA), Iradimed (IRMD), Immune Design (IMDZ) and Savara (SVRA).
What other stocks do shareholders of NewLink Genetics own?
Who are NewLink Genetics' key executives?
NewLink Genetics' management team includes the folowing people:
- Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
- Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
- Mr. Brian Wiley, Chief Commercial Officer (Age 51)
- Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
- Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)
Who are NewLink Genetics' major shareholders?
NewLink Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.03%), Connor Clark & Lunn Investment Management Ltd. (1.70%), Geode Capital Management LLC (1.34%), Geode Capital Management LLC (1.34%), Two Sigma Investments LP (1.22%) and Dimensional Fund Advisors LP (1.01%). Company insiders that own NewLink Genetics stock include Carl W Langren, Ernest Talarico III and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.
Which major investors are selling NewLink Genetics stock?
Which major investors are buying NewLink Genetics stock?
NLNK stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, SG Americas Securities LLC, Acadian Asset Management LLC, Bank of New York Mellon Corp, Two Sigma Advisers LP, Paloma Partners Management Co and Geode Capital Management LLC. View Insider Buying and Selling for NewLink Genetics.
How do I buy shares of NewLink Genetics?
Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NewLink Genetics' stock price today?
One share of NLNK stock can currently be purchased for approximately $1.90.
How big of a company is NewLink Genetics?
NewLink Genetics has a market capitalization of $70.82 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.
What is NewLink Genetics' official website?
How can I contact NewLink Genetics?
NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE SUITE 5100, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]
MarketBeat Community Rating for NewLink Genetics (NASDAQ NLNK)
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
